Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- suspected CAD for which an indication to PCI is given: both patients with stable CAD, and stable post-acute coronary syndromes (ACS), both with ST-segment elevation (STEMI) and without ST-segment elevation (NSTE-ACS) patients, provided that markers of myocardial necrosis (CK-MB, troponins) are stabilized (i.e., with variations \<20% in two consecutive measurements obtained at ≥6 h time distance before PCI, according to the universal definition of peri-procedural myocardial infarction).~Exclusion Criteria:~* any previously known increase in liver enzymes (AST, ALT) ascribed to liver dysfunction at baseline;~* history of liver toxicity or myopathy on previous treatment with statins;~* left ventricular ejection fraction \<30%;~* renal insufficiency, with creatinine \>2 mg/dL at baseline;~* ongoing treatment with high-dose statins (atorvastatin 80 mg/d or rosuvastatin 40 mg/d);~* pregnant or lactating women.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- twice placebo before PCI (Type: PLACEBO_COMPARATOR): None
- atorvastatin 80 + 40 mg pre PCI (Type: EXPERIMENTAL): None
- rosuvastatin 40 + 40 mg before PCI (Type: EXPERIMENTAL): None
- rosuvastatin 5 + ezetimibe 10 mg twice before PCI (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).